RxDoctor Payments Data

Charles Boackle, MD

Internal Medicine · Birmingham, ALNPI 1104935287

Payments from drug & device makers

$10,131in general payments, 2019–2025

Across 627 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$952
  • Lilly USA, LLC$898
  • Novo Nordisk$885
  • Amarin Pharma, Inc.$699
  • Amgen$623
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$10,086100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,131 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$94,923
Medicare patients
175
Services billed
2,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$73,223
JardianceEmpagliflozin53$67,088
RybelsusSemaglutide26$46,171
JanuviaSitagliptin Phosphate41$36,639
Janumet XrSitagliptin Phos/Metformin Hcl28$31,154
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$23,865
EliquisApixaban36$23,391
TradjentaLinagliptin22$19,236
Tresiba Flextouch U-200Insulin Degludec15$16,702
MyrbetriqMirabegron17$15,670
FarxigaDapagliflozin Propanediol16$15,213
GlyxambiEmpagliflozin/Linagliptin16$13,951
Synjardy XrEmpagliflozin/Metformin Hcl14$13,438
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$9,250
Risedronate Sodium28$5,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$885$119,39478 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr$140$113,714105 claims
MerckJanuvia, Janumet Xr$207$67,79469 claims
GSKTrelegy Ellipta, Anoro Ellipta$413$33,11542 claims
PfizerEliquis$952$23,39136 claims
Astellas Pharma US IncMyrbetriq$258$15,67017 claims
AstraZenecaFarxiga$152$15,21316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →